Dominik Plonner
PAUL HARTMANN AG
dominik.plonner@hartmann.info
+49 7321 36 1312
dominik.plonner@hartmann.info
+49 7321 36 1312
- Solid growth in core medical segments: nine-month sales rise by 3.2 percent to EUR 1,563.9 million.
- EBIT within expected range at EUR 90.3 million.
- 2018 outlook for sales and EBIT confirmed.
Heidenheim, November 11, 2018. From January to September 2018, the HARTMANN GROUP, a leading international supplier of medical and hygiene products, increased group sales to EUR 1,563.9 million, despite difficult market conditions. This reflects a moderate increase of 3.2 percent compared to the previous year.
Earnings before interest and taxes (EBIT) were EUR 90.3 million (previous year: EUR 93.4 million), and thereby 3.3 percent below the figure from 2017. The slight decrease in EBIT is primarily due to general price pressure in the sales markets, continued high regulatory expenses, and strategic expenses for structural and growth investments. HARTMANN continues to boast a strong financial standing with a solid net financial position of EUR 66 million, and an equity ratio of more than 60 percent.
The third quarter of 2018 confirms HARTMANN’s competitive position. “We were able to compensate for the effects of price pressure and currency exchange effects, while maintaining our growth path,” says Andreas Joehle, Chairman of the Management Board of Paul Hartmann AG. “Despite expenses resulting from structural and growth projects, investment in the sales organizations, and the implementation of the Medical Device Regulation, EBIT was in line with our expectations.” Based on the results for the first nine months, HARTMANN confirms its outlook for the full-year 2018, which foresees moderate growth in sales and a moderate decline in EBIT. Joehle continues: “With its strategic investments, HARTMAN will achieve a competitive edge in the medium to long term and open up new market potential for sustained success in the future.”
Earnings before interest and taxes (EBIT) were EUR 90.3 million (previous year: EUR 93.4 million), and thereby 3.3 percent below the figure from 2017. The slight decrease in EBIT is primarily due to general price pressure in the sales markets, continued high regulatory expenses, and strategic expenses for structural and growth investments. HARTMANN continues to boast a strong financial standing with a solid net financial position of EUR 66 million, and an equity ratio of more than 60 percent.
The third quarter of 2018 confirms HARTMANN’s competitive position. “We were able to compensate for the effects of price pressure and currency exchange effects, while maintaining our growth path,” says Andreas Joehle, Chairman of the Management Board of Paul Hartmann AG. “Despite expenses resulting from structural and growth projects, investment in the sales organizations, and the implementation of the Medical Device Regulation, EBIT was in line with our expectations.” Based on the results for the first nine months, HARTMANN confirms its outlook for the full-year 2018, which foresees moderate growth in sales and a moderate decline in EBIT. Joehle continues: “With its strategic investments, HARTMAN will achieve a competitive edge in the medium to long term and open up new market potential for sustained success in the future.”
Solid growth in the core medical segments
The Wound Management segment achieved sales of EUR 351.4 million, exceeding its results in the previous year by 3.9 percent. The growth is primarily attributable to the rising demand for super-absorbent and anti-bacterial wound dressings, the HydroTherapy treatment concept, and the Personal Healthcare segment.
The Incontinence Management segment grew its sales by 5.4 percent to EUR 516.8 million. The inclusion of sales achieved by LINDOR, whose integration is running in line with expectations, more than compensated for the negative effects of exchange rates. The Skintegrity Concept of holistic incontinence management and IAD (incontinence-associated dermatitis) prevention continued to increase their contributions to the business segment’s sales growth in the third quarter.
The Infection Management segment increased its sales by 2.0 percent to EUR 372.7 million. Thanks to moderate organic growth of 3.6 percent, the sales of surgical products and examination gloves exceeded the figure from the previous year despite exchange rate effects, as did the sales of disinfection management solutions. The Other Group Activities segment achieved sales of EUR 323million, which represented a slight increase of 0.6 percent as compared to the previous year.
The rise in group sales revenues was mainly based on positive developments in European countries outside the group’s domestic market. Europe as a whole (not including Germany) achieved an increase of 5.7 percent. In Germany, HARTMANN exceeded the previous year’s figure by 1.2 percent. Outside of Europe, moderate growth of 2.6 percent was overshadowed by negative exchange rate effects.
About the HARTMANN GROUP
The HARTMANN GROUP is one of the leading European providers of professional medical and care products and associated services. Every day, healthcare professionals and patients rely on HARTMANN brands in the segments of Incontinence Management (e.g. MoliCare®), Wound Care (e.g. Zetuvit®, Cosmopor®) and Infection Management (e. g. Sterillium®). This is expressed in our brand promise of “Helps. Cares. Protects.” HARTMANN generated sales of EUR 2.3 billion in the 2023 financial year. Founded in 1818, the Company sells its products and solutions in 130 countries around the world. For the future, the HARTMANN GROUP is currently implementing its strategic Transformation Program with its high-performance, customer-oriented and passionate team.
To learn more about the HARTMANN GROUP, visit www.corporate.hartmann.info.